Monogram Technologies INC 8-K filings

Monogram Technologies Inc. has entered into a selling agency agreement for a best efforts offering of up to 4,444,445 units, each consisting of preferred stock and a common stock purchase warrant, aiming to raise up to $10 million.

Monogram Orthopaedics Inc. has changed its corporate name to Monogram Technologies Inc., effective May 15, 2024, to better reflect its focus on AI-driven robotics and broader technology applications.

Monogram Orthopaedics announced its first quarter 2024 financial results and provided an update on its progress towards FDA 510(k) submission, now expected in the second half of 2024.

Monogram Orthopaedics is progressing towards a 510(k) submission for its mBs surgical system in the second half of 2024, following constructive feedback from the FDA.

Monogram Orthopaedics has updated its stock purchase agreement with B. Riley Principal Capital II and clarified its status with the NVIDIA Inception Program.

Monogram Orthopaedics released an investor presentation detailing their financial results for 2023 and provided an update on their regulatory strategy for their mBs robotic system.

Monogram Orthopaedics Inc. has filed an amendment to its charter, eliminating multiple classes of preferred stock and establishing a classified board of directors with staggered terms.

Monogram Orthopaedics reports its 2023 financial results, highlighting progress on its mBs surgical robot and mVision technology, with a 510(k) submission targeted for the second half of 2024.